April 4, 2026
From silence to spicy comments
Deafness reversed: One injection restores hearing in just weeks – ScienceDaily
One shot brings back hearing — hope, side‑eye, and big questions
TLDR: A one-shot gene therapy restored hearing in 10 people with a specific genetic cause, with kids seeing the biggest gains. Commenters are thrilled but split: some want tinnitus cures, others note the story’s from last year, and many ask if non-genetic cases like rubella would benefit.
The internet did a double take at a study claiming a single gene‑therapy shot helped people born deaf start hearing within weeks — and the comments came in loud and clear. Ten patients in China, ages 1 to 24, all improved after doctors injected a repaired version of the OTOF gene into the inner ear using AAV (a harmless virus courier). Results were fast, stronger in kids, and published in Nature Medicine. Cue the comment fireworks.
The cheer squad showed up first. “Holy moley,” one fan gushed, begging for a tinnitus fix next — because if hearing can be restored, can the ringing go too? Then the fact‑checkers barged in with receipts: this news is from July last year, so where are the follow‑ups? The vibe shifted from “miracle” to “wait, is this just recycled hype?” Finally, the practical crowd chimed in with real‑world worries: would this help people whose hearing loss came from infections like rubella before birth — not genes? Short answer: this shot targets a specific gene, so it’s not a one‑size‑fits‑all cure.
Between celebration and skepticism, the thread served peak internet energy. Fans want faster trials and tinnitus answers, skeptics want fresh data, and the cautious ask who actually benefits. For those craving details, Karolinska’s summary is here: news.ki.se. The science is turning up the volume — the comments are blasting the questions.
Key Points
- •Ten patients (ages 1–24) with OTOF-related congenital deafness were treated across five hospitals in China.
- •A single AAV-mediated OTOF gene therapy was delivered via round window injection into the inner ear.
- •Hearing improvements began within one month for most patients; all improved by six months.
- •Average sound detection improved from 106 dB to 52 dB, with strongest gains in children aged 5–8.
- •Therapy was well-tolerated; decreased neutrophils was the most common side effect, with no serious adverse events over 6–12 months.